22nd Century Group Inc (XXII) Lowered to Hold at Zacks Investment Research
Zacks Investment Research downgraded shares of 22nd Century Group Inc (NYSE:XXII) from a buy rating to a hold rating in a research note issued to investors on Friday.
According to Zacks, “22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company’s products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York. “
Shares of 22nd Century Group (XXII) opened at 2.24 on Friday. 22nd Century Group has a 1-year low of $0.81 and a 1-year high of $2.84. The firm’s market cap is $230.18 million. The company’s 50-day moving average price is $1.90 and its 200 day moving average price is $1.46.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/22nd-century-group-inc-xxii-lowered-to-hold-at-zacks-investment-research/1528672.html.
In related news, VP Michael Robert Moynihan sold 29,532 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $2.00, for a total value of $59,064.00. Following the completion of the transaction, the vice president now owns 917,220 shares of the company’s stock, valued at $1,834,440. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of 22nd Century Group by 17.6% in the second quarter. Vanguard Group Inc. now owns 2,894,322 shares of the biotechnology company’s stock worth $5,065,000 after buying an additional 432,450 shares during the period. National Asset Management Inc. increased its position in shares of 22nd Century Group by 13.7% in the first quarter. National Asset Management Inc. now owns 172,000 shares of the biotechnology company’s stock worth $204,000 after buying an additional 20,700 shares during the period. Northern Trust Corp increased its position in shares of 22nd Century Group by 22.3% in the second quarter. Northern Trust Corp now owns 133,797 shares of the biotechnology company’s stock worth $234,000 after buying an additional 24,401 shares during the period. Finally, Virtu KCG Holdings LLC increased its position in shares of 22nd Century Group by 300.9% in the second quarter. Virtu KCG Holdings LLC now owns 126,106 shares of the biotechnology company’s stock worth $221,000 after buying an additional 94,650 shares during the period.
About 22nd Century Group
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for 22nd Century Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.